Authors
Nazia Rashid, Krithika Rajagopalan, Vinod Kumar Yakkala
Published in
Neurology and therapy. Nov 13, 2026. Epub Nov 13, 2026.
Abstract
Trofinetide (TRO) approval by the US FDA enabled participants from the placebo-controlled (LAVENDER) and open-label extension (LILAC-1 and LILAC-2) trials to continue TRO commercially. We assessed participant characteristics, adverse events (AEs), dosing patterns, and time on TRO among LILAC-2 participants who continued or did not continue TRO post-approval.
This retrospective post hoc analysis used participant-level data from the LAVENDER, LILAC-1, and LILAC-2 trials linked with specialty-pharmacy data to categorize TRO continuers and non-continuers by post-launch prescription (RX) shipment status. Demographics (e.g., age, race) were evaluated at baseline (LAVENDER). Outcomes included Rett Syndrome Behavior Questionnaire (RSBQ) total and domain scores, Clinical Global Impression-Improvement (CGI-I) score from baseline through LILAC-2, highest recorded AE severity for each AE during LILAC-2, and dosing patterns (mean twice-daily dose by volume [ml], weight [mg/kg]; percent target daily dose [%TDD]) pre- and post-launch. Post-launch treatment persistence (allowable RX shipment gap ≤ 90 days) and time on TRO were also assessed.
Among 77 LILAC-2 participants alive and eligible (n = 73) to shift to real-world usual care, 57/73 (78.1%) were classified as TRO continuers; the rest were non-continuers. Baseline mean age was 10.5 vs 11.9 years; most were white (89.5% vs 100.0%). Both groups achieved clinically meaningful total RSBQ improvement from baseline to LILAC-2 week 52 (8.2 and 6.2 points), with improvements also observed across RSBQ domains and CGI-I. AEs were predominantly mild to moderate, especially among continuers. TRO continuers showed gradual dose reduction during trials with stabilization post-launch (~ 40 ml), while TRO non-continuers showed fluctuations throughout; post-launch %TDD showed minimal change of ~ 92.7% (month 1) and ~ 91.0% (month 12) among TRO continuers. Average time on TRO among continuers was 4.3 years from baseline through available real-world follow-up.
Approximately 75% of LILAC-2 participants continued TRO post-approval; all persisted for ≥ 12 months post-launch and exhibited stable dosing patterns. Both groups demonstrated clinically meaningful RSBQ improvements through week 52 of LILAC-2 and predominantly mild-to-moderate AEs during LILAC-2.
PMID:
43024143
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 62
- Comments 0